111 related articles for article (PubMed ID: 22746837)
1. Optimization and internalization mechanisms of PEGylated adenovirus vector with targeting peptide for cancer gene therapy.
Yao XL; Yoshioka Y; Ruan GX; Chen YZ; Mizuguchi H; Mukai Y; Okada N; Gao JQ; Nakagawa S
Biomacromolecules; 2012 Aug; 13(8):2402-9. PubMed ID: 22746837
[TBL] [Abstract][Full Text] [Related]
2. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.
Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Kawai Y; Mizuguchi H; Gao JQ; Mukai Y; Okada N; Nakagawa S
Mol Ther; 2011 Sep; 19(9):1619-25. PubMed ID: 21673661
[TBL] [Abstract][Full Text] [Related]
3. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus vector covalently conjugated to polyethylene glycol with a cancer-specific promoter suppresses the tumor growth through systemic administration.
Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Biol Pharm Bull; 2010; 33(6):1073-6. PubMed ID: 20522982
[TBL] [Abstract][Full Text] [Related]
5. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration.
Gao JQ; Eto Y; Yoshioka Y; Sekiguchi F; Kurachi S; Morishige T; Yao X; Watanabe H; Asavatanabodee R; Sakurai F; Mizuguchi H; Okada Y; Mukai Y; Tsutsumi Y; Mayumi T; Okada N; Nakagawa S
J Control Release; 2007 Sep; 122(1):102-10. PubMed ID: 17628160
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor (EGF) receptor targeted delivery of PEGylated adenovirus.
Park JW; Mok H; Park TG
Biochem Biophys Res Commun; 2008 Feb; 366(3):769-74. PubMed ID: 18083120
[TBL] [Abstract][Full Text] [Related]
7. Functional improvement of an IRQ-PEG-MEND for delivering genes to the lung.
Ishitsuka T; Akita H; Harashima H
J Control Release; 2011 Aug; 154(1):77-83. PubMed ID: 21619903
[TBL] [Abstract][Full Text] [Related]
8. Transduction of adenovirus vectors modified with cell-penetrating peptides.
Eto Y; Yoshioka Y; Asavatanabodee R; Kida S; Maeda M; Mukai Y; Mizuguchi H; Kawasaki K; Okada N; Nakagawa S
Peptides; 2009 Aug; 30(8):1548-52. PubMed ID: 19467282
[TBL] [Abstract][Full Text] [Related]
9. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis.
Yao X; Yoshioka Y; Morishige T; Eto Y; Watanabe H; Okada Y; Mizuguchi H; Mukai Y; Okada N; Nakagawa S
Gene Ther; 2009 Dec; 16(12):1395-404. PubMed ID: 19641532
[TBL] [Abstract][Full Text] [Related]
10. Folate immobilized and PEGylated adenovirus for retargeting to tumor cells.
Oh IK; Mok H; Park TG
Bioconjug Chem; 2006; 17(3):721-7. PubMed ID: 16704210
[TBL] [Abstract][Full Text] [Related]
11. PEGylated adenovirus for targeted gene therapy.
O'Riordan CR; Song A
Methods Mol Biol; 2008; 434():133-60. PubMed ID: 18470643
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of chitosan-PEG-folate-complexed oncolytic adenovirus for active and systemic cancer gene therapy.
Kwon OJ; Kang E; Choi JW; Kim SW; Yun CO
J Control Release; 2013 Aug; 169(3):257-65. PubMed ID: 23562633
[TBL] [Abstract][Full Text] [Related]
13. Hexon-specific PEGylated adenovirus vectors utilizing avidin-biotin interaction.
Suzuki-Kouyama E; Katayama K; Sakurai F; Yamaguchi T; Kurachi S; Kawabata K; Nakagawa S; Mizuguchi H
Biomaterials; 2011 Feb; 32(6):1724-30. PubMed ID: 21106235
[TBL] [Abstract][Full Text] [Related]
14. Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency.
Yoshioka Y; Asavatanabodee R; Eto Y; Watanabe H; Morishige T; Yao X; Kida S; Maeda M; Mukai Y; Mizuguchi H; Kawasaki K; Okada N; Nakagawa S
Life Sci; 2008 Nov; 83(21-22):747-55. PubMed ID: 18930744
[TBL] [Abstract][Full Text] [Related]
15. Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer.
Eto Y; Yoshioka Y; Ishida T; Yao X; Morishige T; Narimatsu S; Mizuguchi H; Mukai Y; Okada N; Kiwada H; Nakagawa S
Biol Pharm Bull; 2010; 33(9):1540-4. PubMed ID: 20823571
[TBL] [Abstract][Full Text] [Related]
16. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers.
Fechner H; Haack A; Wang H; Wang X; Eizema K; Pauschinger M; Schoemaker R; Veghel R; Houtsmuller A; Schultheiss HP; Lamers J; Poller W
Gene Ther; 1999 Sep; 6(9):1520-35. PubMed ID: 10490761
[TBL] [Abstract][Full Text] [Related]
17. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
18. Enhanced gene transfection efficiency in CD13-positive vascular endothelial cells with targeted poly(lactic acid)-poly(ethylene glycol) nanoparticles through caveolae-mediated endocytosis.
Liu C; Yu W; Chen Z; Zhang J; Zhang N
J Control Release; 2011 Apr; 151(2):162-75. PubMed ID: 21376765
[TBL] [Abstract][Full Text] [Related]
19. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells.
Fechner H; Wang X; Wang H; Jansen A; Pauschinger M; Scherübl H; Bergelson JM; Schultheiss HP; Poller W
Gene Ther; 2000 Nov; 7(22):1954-68. PubMed ID: 11127584
[TBL] [Abstract][Full Text] [Related]
20. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction.
Park JW; Mok H; Park TG
J Control Release; 2010 Mar; 142(2):238-44. PubMed ID: 19913577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
